Oxazolidinone antibiotics

Daniel J Diekema; Ronald N Jones

doi:10.1016/s0140-6736(01)06964-1

Back

Journal article

Peer reviewed

Oxazolidinone antibiotics

Daniel J Diekema and Ronald N Jones

The Lancet (British edition), Vol.358(9297), pp.1975-1982

12/08/2001

DOI: 10.1016/s0140-6736(01)06964-1

PMID: 11747939

View Online

Abstract

Many common gram-positive pathogens (eg, Staphylococcus aureus, Enterococcus spp, and Streptococcus pneumoniae) have become increasingly resistant to antimicrobial agents, and new drugs with activity against gram-positive bacteria are urgently needed. The oxazolidinones, a new chemical class of synthetic antimicrobial agent, have a unique mechanism of inhibiting bacterial protein synthesis. Linezolid, the first oxazolidinone to be approved for clinical use, displays in-vitro activity (generally bacteriostatic) against many important resistant pathogens, including meticillin-resistant Staph aureus, vancomycin-resistant enterococci, and penicillin-resistant Strep pneumoniae. Linezolid is a parenteral agent that also possesses near-complete oral bioavailability plus favourable pharmacokinetic and toxic effect profiles. Clinical trials confirm the activity of linezolid in the setting of pneumonia, skin and soft-tissue infections, and infections due to vancomycin-resistant enterococci. Linezolid shows promise as an alternative to glycopeptides and streptogramins to treat serious infections due to resistant gram-positive organisms. New agents with greater potency and new spectra of activity could arise from further modification of the oxazolidinone nucleus.

Linezolid

Protein Synthesis Inhibitors - chemistry

Humans

Acetamides - pharmacology

Clinical Trials as Topic

Oxazolidinones - chemistry

Oxazolidinones - therapeutic use

Anti-Bacterial Agents - therapeutic use

Drug Resistance, Microbial

Acetamides - chemistry

Animals

Acetamides - therapeutic use

Oxazolidinones - pharmacology

Anti-Bacterial Agents - chemistry

Anti-Bacterial Agents - pharmacology

Protein Synthesis Inhibitors - pharmacology

Gram-Positive Bacterial Infections - drug therapy

Protein Synthesis Inhibitors - therapeutic use

Details

Title: Subtitle: Oxazolidinone antibiotics
Creators: Daniel J Diekema - Division of Infectious Diseases, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA. daniel-diekema@uiowa.edu
Ronald N Jones
Resource Type: Journal article
Publication Details: The Lancet (British edition), Vol.358(9297), pp.1975-1982
Publisher: England
DOI: 10.1016/s0140-6736(01)06964-1
PMID: 11747939
ISSN: 0140-6736
eISSN: 1474-547X
Language: English
Date published: 12/08/2001
Academic Unit: Infectious Diseases; Pathology; Internal Medicine
Record Identifier: 9983986363102771

Metrics

20 Record Views

330 Times Cited - Web of Science

See more details